Joanne Wuensch
Stock Analyst at Citigroup
(4.48)
# 319
Out of 4,711 analysts
379
Total ratings
64.68%
Success rate
13.44%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Buy | $57 → $50 | $35.91 | +39.24% | 13 | Dec 11, 2024 | |
| SYK Stryker | Maintains: Buy | $411 → $450 | $364.60 | +23.42% | 12 | Dec 11, 2024 | |
| SGHT Sight Sciences | Maintains: Neutral | $5.8 → $4.6 | $3.57 | +28.85% | 9 | Dec 11, 2024 | |
| PEN Penumbra | Maintains: Neutral | $200 → $245 | $242.54 | +1.01% | 24 | Dec 11, 2024 | |
| NVRO Nevro | Maintains: Neutral | $6 → $5 | $3.79 | +31.93% | 19 | Dec 11, 2024 | |
| JNJ Johnson & Johnson | Maintains: Buy | $185 → $175 | $144.47 | +21.13% | 12 | Dec 11, 2024 | |
| ISRG Intuitive Surgical | Maintains: Buy | $567 → $640 | $524.43 | +22.04% | 15 | Dec 11, 2024 | |
| ITGR Integer Holdings | Maintains: Neutral | $130 → $145 | $133.67 | +8.48% | 4 | Dec 11, 2024 | |
| PODD Insulet | Maintains: Buy | $283 → $310 | $266.57 | +16.29% | 13 | Dec 11, 2024 | |
| EW Edwards Lifesciences | Maintains: Buy | $81 → $83 | $74.81 | +10.95% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $80.04 | +13.69% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $29.50 | +18.64% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $107 | $88.95 | +20.29% | 33 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $6.15 | +21.95% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $22 | $18.00 | +22.22% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $150.88 | +7.37% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $115 | $93.44 | +23.07% | 19 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $21.80 | +0.92% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $92 | $81.03 | +13.54% | 18 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $40.01 | +24.97% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $90.39 | +21.69% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $75.44 | +12.67% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $107.12 | +12.02% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $103 | $78.91 | +30.53% | 2 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $128 | $114.23 | +12.05% | 19 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $227.68 | +9.80% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $84.76 | -18.59% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $237.27 | -46.47% | 6 | Dec 10, 2018 |
Tandem Diabetes Care
Dec 11, 2024
Maintains: Buy
Price Target: $57 → $50
Current: $35.91
Upside: +39.24%
Stryker
Dec 11, 2024
Maintains: Buy
Price Target: $411 → $450
Current: $364.60
Upside: +23.42%
Sight Sciences
Dec 11, 2024
Maintains: Neutral
Price Target: $5.8 → $4.6
Current: $3.57
Upside: +28.85%
Penumbra
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $242.54
Upside: +1.01%
Nevro
Dec 11, 2024
Maintains: Neutral
Price Target: $6 → $5
Current: $3.79
Upside: +31.93%
Johnson & Johnson
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $144.47
Upside: +21.13%
Intuitive Surgical
Dec 11, 2024
Maintains: Buy
Price Target: $567 → $640
Current: $524.43
Upside: +22.04%
Integer Holdings
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $133.67
Upside: +8.48%
Insulet
Dec 11, 2024
Maintains: Buy
Price Target: $283 → $310
Current: $266.57
Upside: +16.29%
Edwards Lifesciences
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $74.81
Upside: +10.95%
Dec 11, 2024
Maintains: Buy
Price Target: $85 → $91
Current: $80.04
Upside: +13.69%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $29.50
Upside: +18.64%
Dec 11, 2024
Maintains: Buy
Price Target: $98 → $107
Current: $88.95
Upside: +20.29%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $6.15
Upside: +21.95%
Dec 11, 2024
Downgrades: Neutral
Price Target: $24 → $22
Current: $18.00
Upside: +22.22%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $150.88
Upside: +7.37%
Dec 6, 2024
Maintains: Buy
Price Target: $116 → $115
Current: $93.44
Upside: +23.07%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $21.80
Upside: +0.92%
Oct 1, 2024
Maintains: Neutral
Price Target: $85 → $92
Current: $81.03
Upside: +13.54%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $40.01
Upside: +24.97%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $90.39
Upside: +21.69%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $75.44
Upside: +12.67%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $107.12
Upside: +12.02%
Apr 3, 2024
Maintains: Buy
Price Target: $88 → $103
Current: $78.91
Upside: +30.53%
Apr 3, 2024
Maintains: Buy
Price Target: $126 → $128
Current: $114.23
Upside: +12.05%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $227.68
Upside: +9.80%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $84.76
Upside: -18.59%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $237.27
Upside: -46.47%